|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma.
|
19788391 |
2010 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1.
|
29392960 |
2018 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on its ability to stimulate cytotoxic T cells, interleukin-2 (IL-2) has been used to treat patients with metastatic melanoma and metastatic kidney cancer.
|
30673115 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our in vitro results may explain, at least in part, the clinical efficacy of combination low-dose IL-2 and IFN-alpha therapy against mRCC.
|
22715591 |
2011 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Twenty one patients with mRCC with sarcomatoid features post-nephrectomy who underwent therapy with HD IL-2 were identified at the University of Pittsburgh Medical Center from 2004 to 2016.
|
29261796 |
2017 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
To analyse and then generalize the mechanism by which partial or complete response is achieved among a limited number of patients with metastatic renal cell carcinoma (RCC) treated with interferon or interleukin-2.
|
24895689 |
2014 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dorsal Muscle Attenuation May Predict Failure to Respond to Interleukin-2 Therapy in Metastatic Renal Cell Carcinoma.
|
28341412 |
2017 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma.
|
15517589 |
2004 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Twenty-nine patients with metastatic renal cell carcinoma and a total of 30 lesions measuring 1.0 cm(2) or greater in accessible thoracic (n = 15) or abdominal (n = 15) locations underwent up to three cycles of six weekly intratumoral IL-2 plasmid DNA injections.
|
15128982 |
2004 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
We retrospectively reviewed the records of patients with metastatic renal cell carcinoma treated with high dose interleukin-2 between July 2007 and September 2014.
|
28288839 |
2017 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data continue to support a recommendation for HD IL-2 for patients with mRCC who meet eligibility criteria.
|
30917871 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor regression induced by IL-2 in a fraction of patients with metastatic renal-cell carcinoma (MRCC) could not be predicted by immunological monitoring.
|
8325704 |
1993 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies have examined the efficacy of using combinations of interferons, interleukin-2, or specific subpopulations of lymphoid cells to control metastatic renal cell carcinoma.
|
1379830 |
1992 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ninety one patients receiving IL2 therapy for metastatic renal cell carcinoma and melanoma at Huntsman Cancer institute (HCI), Utah from May 2009 to October 2016 were retrospectively evaluated for rigor prophylaxis.
|
30342473 |
2018 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma.
|
11956426 |
2002 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The previously published "SELECT" trial of high-dose aldesleukin (HD-IL2) for metastatic renal cell carcinoma resulted in an objective response rate of 25%.
|
27742794 |
2017 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dynamic contrast-enhanced computed tomography scans were performed at baseline and after 5 and 10 weeks' treatment in 69 prospectively included mRCC patients receiving treatment with interferon alpha and interleukin 2 (n = 26); interferon alpha, interleukin 2, and bevacizumab (n = 24); sunitinib (n = 7); pazopanib (n = 5); or temsirolimus (n = 7).
|
27513367 |
2017 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The timing of the event was categorized as occurring before, during or after IL-2 or related to any checkpoint inhibitor (CPI). mM patients and mRCC patients were analyzed separately.
|
29254506 |
2017 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
We examined peripheral blood lymphocyte (PBL) gene expression as a biomarker of illness and treatment effect using the Affymetrix Human Gene ST1 platform in patients with metastatic renal cell carcinoma (mRCC) who received combined treatment with IL-2, interferon-?-2a and dendritic cell vaccine.
|
23226513 |
2012 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Currently, seven targeted agents are approved for use in metastatic renal cell carcinoma and have superseded the use of parenteral cytokine therapy with interleukin-2 or interferon, the former standards of care for metastatic renal cell carcinoma.
|
26625878 |
2017 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, we analyzed antibody and T-cell responses against wt p53 15-mer peptides in patients with metastatic renal cell carcinoma who were alive with no evidence of disease after a follow-up period of minimum 5 years after treatment with IL-2 ± IFN-α ± histamine containing immunotherapy to identify novel epitopes for use in immunotherapy and for potential response biomarkers.
|
21989411 |
2012 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma.
|
9010039 |
1997 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adoptive immunotherapy using interleukin-2 (IL-2) based therapy can result in marked tumor regression in some patients with metastatic renal cell carcinoma.
|
8341057 |
1993 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination therapy with systemically administered interleukin-2 (IL-2) and interferon alpha (IFN-alpha) has resulted in long-term objective remissions in 30% of patients with metastatic renal cell carcinoma (RCC), but toxic effects are clinically significant.
|
8423625 |
1993 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 305 patients with metastatic renal cell carcinoma or melanoma treated with HD IL-2 over a 12-year period were reviewed.
|
29165819 |
2018 |